The International Conference on Harmonization (ICH) Common Technical Document (CTD) format is the submission standard for new and abbreviated drug product applications in the United States, the European Union and Japan. One of the significant sections of the CTD is the Pharmaceutical Development Report (PDR). A complete PDR is essential to provide a comprehensive understanding of the product and process for the FDA application reviewers and inspectors. The information in the PDR is based upon the documentation generated during the formulation and process development phase of drug development.
The ICH Q8 and Q8(R1) Pharmaceutical Development Report guidance documents provide the guidelines for the PDR. As stated in the Q8 guidance, “The Pharmaceutical Development section provides an opportunity to present the knowledge gained through the application of scientific approaches and quality risk management to the development of a product and its manufacturing process.” The PDR can, and should, be updated over the lifecycle of the product as new knowledge of the product is obtained.
There are six critical sections to PDR development listed in the Q8 guidance document. Each section addresses a specific component or process in the development process, including:
1. Components of the drug product
2. Information about the drug product formulation development, overages, and physiochemical and biological properties
3. Describes the manufacturing process development
4. Rationale for the choice of the drug product container closure
5. Rationale for selecting the preservative systems and performing, or not performing, the compendial microbial limits and antimicrobial effectiveness tests
6. Compatibility of the drug product with reconstitution diluents or dilution prior to administration for labeling information
- White Paper: Basic Elements of a Successful CAPA Program
- Always welcome, a clear, succinct white paper on the fundamentals of CAPA. ...
- How QbD is Changing Drug Development
- Pharmaceutical development has always walked a bit of a tightrope between the need to get safe, efficacious and hopefully profitable...
- Pharmaceutical “Quality by Design” (QbD): An Introduction, Process Development and Applications
- AskAboutValidation.com posted a really great Quality by Design overview piece in late 2012....
- Pharmaceutical Quality by Design: Is It Time to Clear the Air?
- This PDF report (previously circulated only in bootleg form) speaks very eloquently, of progress, of good intentions, of great and...
- A Practical Roadmap to Pharmaceutical Process Validation
- A staged and structured approach can allow organizations to make the most of FDA’s new process validation guidance ...